Literature DB >> 21263314

Plasma levels of tumor necrosis factor-α and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase.

Cho-Kai Wu1, Jen-Kuang Lee, Fu-Tien Chiang, Chic-Hsin Yang, Shui-Wei Huang, Juey-Jen Hwang, Jiunn-Lee Lin, Chuen-Den Tseng, Jin-Jer Chen, Chia-Ti Tsai.   

Abstract

OBJECTIVE: The inflammatory process is associated with cardiac diastolic dysfunction, which has been demonstrated to be an independent prognostic marker for the mortality of critically ill patients. We investigated the association among inflammatory cytokines (tumor necrosis factor-α and interleukin-6), diastolic heart failure, and the possible molecular mechanism.
DESIGN: Prospective case-controlled cohort and molecular studies.
SETTING: University hospital and research laboratory.
SUBJECTS: Patients with a diagnosis of diastolic heart failure by echocardiography and matched control subjects from the general population (study group 1) and also subjects from the intensive care unit (study group 2). Sarcoplasmic reticulum Ca2+-ATPase (SERCA2) gene expression and diastolic calcium decay in HL-1 cardiomyocytes were used as molecular phenotypes of diastolic heart failure.
INTERVENTIONS: Soluble plasma levels of tumor necrosis factor-α and interleukin-6 were measured in all subjects. An approximate 1.75-kb promoter of the SERCA2 gene was cloned to the pGL3 luciferase reporter. The effect of tumor necrosis factor-α and interleukin-6 on SERCA2 gene expression and diastolic calcium decay of HL-1 cardiomyocytes were investigated.
MEASUREMENTS AND MAIN RESULTS: Patients with diastolic heart failure had significantly higher plasma levels of tumor necrosis factor-α and interleukin-6 than the control subjects. Significant correlations (p < .01 for each) were found for tumor necrosis factor-α and E/Em (r = .87) and E/A (r = -0.69), and for interleukin-6 and E/Em (r = .80) and E/A (r = -0.65). Cytokine levels were also correlated with diastolic function in critically ill patients (study group 2), and diastolic function improved significantly in association with decrease of cytokines. Tumor necrosis factor-α, interleukin-6, and sera from critically ill patients downregulated the expression of the SERCA2 gene. Tumor necrosis factor-α and interleukin-6 also delayed the diastolic calcium reuptake and decay in cardiomyocytes.
CONCLUSIONS: Through downregulation of SERCA2 gene expression, inflammatory cytokines may cause cardiac diastolic dysfunction by decreasing diastolic calcium reuptake. Our study may suggest novel therapeutic strategies for diastolic heart failure and critically ill patients by modulating inflammatory reactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21263314     DOI: 10.1097/CCM.0b013e31820a91b9

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  46 in total

1.  Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure.

Authors:  Hiroki Matsumoto; Takatoshi Kasai; Akihiro Sato; Sayaki Ishiwata; Shoichiro Yatsu; Jun Shitara; Azusa Murata; Takao Kato; Shoko Suda; Yuya Matsue; Masaru Hiki; Atsutoshi Takagi; Hiroyuki Daida
Journal:  Heart Vessels       Date:  2019-05-18       Impact factor: 2.037

2.  Portal congestion and intestinal edema in hospitalized patients with heart failure.

Authors:  Yuki Ikeda; Shunsuke Ishii; Mayu Yazaki; Teppei Fujita; Yuichiro Iida; Toyoji Kaida; Takeru Nabeta; Eiji Nakatani; Emi Maekawa; Tomoyoshi Yanagisawa; Toshimi Koitabashi; Takayuki Inomata; Junya Ako
Journal:  Heart Vessels       Date:  2018-01-11       Impact factor: 2.037

3.  Use of insulin to decrease septic shock-induced myocardial depression in a porcine model.

Authors:  Yosef Levenbrown; Scott Penfil; Elena Rodriguez; Yan Zhu; Jobayer Hossain; A Majeed Bhat; Anne Hesek; Karen B O'Neil; Kelly Tobin; Thomas H Shaffer
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

Review 4.  Reappraisal of Inflammatory Biomarkers in Heart Failure.

Authors:  Thanat Chaikijurajai; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2020-02

5.  New insights into weaning from mechanical ventilation: left ventricular diastolic dysfunction is a key player.

Authors:  John Papanikolaou; Demosthenes Makris; Theodosios Saranteas; Dimitrios Karakitsos; Elias Zintzaras; Andreas Karabinis; Georgia Kostopanagiotou; Epaminondas Zakynthinos
Journal:  Intensive Care Med       Date:  2011-10-06       Impact factor: 17.440

6.  Cardioprotective effects of rutin via alteration in TNF-α, CRP, and BNP levels coupled with antioxidant effect in STZ-induced diabetic rats.

Authors:  Ravi Saklani; Suresh Kumar Gupta; Ipseeta Ray Mohanty; Binit Kumar; Sushma Srivastava; Rajani Mathur
Journal:  Mol Cell Biochem       Date:  2016-07-22       Impact factor: 3.396

7.  Diastolic Dysfunction Increases the Risk of Primary Graft Dysfunction after Lung Transplant.

Authors:  Mary K Porteous; Bonnie Ky; James N Kirkpatrick; Russell Shinohara; Joshua M Diamond; Rupal J Shah; James C Lee; Jason D Christie; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

Review 8.  The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction.

Authors:  Samantha D Francis Stuart; Nicole M De Jesus; Merry L Lindsey; Crystal M Ripplinger
Journal:  J Mol Cell Cardiol       Date:  2015-12-29       Impact factor: 5.000

Review 9.  Arrhythmogenic mechanisms of obstructive sleep apnea in heart failure patients.

Authors:  Karan R Chadda; Ibrahim T Fazmin; Shiraz Ahmad; Haseeb Valli; Charlotte E Edling; Christopher L-H Huang; Kamalan Jeevaratnam
Journal:  Sleep       Date:  2018-09-01       Impact factor: 5.849

10.  Dissecting the mechanisms of left ventricular diastolic dysfunction and inflammation in peritoneal dialysis patients.

Authors:  Cho-Kai Wu; Yin-Tsen Huang; Heng-Hsu Lin; Chung-Yi Yang; Yu-Chung Lien; Jen-Kuang Lee; Jenq-Wen Huang; Kuan-Yu Hung
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.